Back to Search

A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)

Recruiting Phase 3 Interventional Study
Atherosclerosis Cardiovascular Disease Chronic Kidney Disease
Ready to participate?

Review the details below, then apply to join this clinical trial.

Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial

The purpose of this study is to measure cardiovascular outcomes with orforglipron compared with placebo in participants with atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney disease (CKD). Participation in the study will last about 5 years.

Trial Locations

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Have established ASCVD and/or CKD Exclusion Criteria: * Have type 1 diabetes * Have had a major heart condition within 60 days prior to screening * Have New York Heart Association Functional Classification Class IV heart failure
Contacts

Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or

317-615-4559

LillyTrials@Lilly.com

CONTACT

Physicians interested in becoming principal investigators please contact

clinical_inquiry_hub@lilly.com

CONTACT

NCT ID: NCT07241390 Source: ClinicalTrials.gov